Bristol-Myers Squibb will no longer make or market Tequin(gatifloxacin) but will not pull current supplies off the market.
Bristol-Myers Squibb will no longer make or market Tequin (gatifloxacin) but will not pull current supplies off the market. The company is returning its rights to Kyorin Pharmaceutical. In February, the FDA and BMS strengthened a warning against the use of Tequin by people with diabetes after reports of problems with high and low blood sugar associated with the drug. The watchdog group Public Citizen has petitioned the FDA to ban the drug, charging that it has caused deaths and hospitalizations.
To see more Hot off the Press news articles, click here click here.
To go to the Drug Topics homepage, click here.
Q&A: Pharmacist-Led Diabetes Management Transforms Patient Care and Clinical Outcomes
June 28th 2025An ambulatory care pharmacist program in Washington State dramatically improved diabetes management by reducing A1c levels, increasing medication adherence, and providing comprehensive patient education.